Capital Asset Advisory Services LLC Sells 4,080 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Asset Advisory Services LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,172 shares of the company's stock after selling 4,080 shares during the period. Capital Asset Advisory Services LLC's holdings in Johnson & Johnson were worth $4,066,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tallon Kerry Patrick bought a new position in Johnson & Johnson in the 4th quarter worth approximately $290,000. Capital & Planning LLC grew its holdings in shares of Johnson & Johnson by 13.6% in the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after buying an additional 183 shares during the period. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson in the 4th quarter worth $85,886,000. Finally, Synergy Asset Management LLC boosted its stake in Johnson & Johnson by 116.2% in the 4th quarter. Synergy Asset Management LLC now owns 12,734 shares of the company's stock worth $1,940,000 after purchasing an additional 6,844 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $1.03 during mid-day trading on Wednesday, reaching $153.39. The company had a trading volume of 6,979,516 shares, compared to its average volume of 7,943,306. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $369.07 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.56 and a beta of 0.42. The business has a fifty day simple moving average of $154.01 and a 200 day simple moving average of $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.